Bidicod Syrup: Each 5 ml syrup contains Butamirate Citrate BP 7.5 mg.
Butamirate Citrate exerts expectorant, moderate bronchodilating and anti-inflammatory action. It is safe and non-sedating which is neither chemically nor pharmacologically related to opium alkaloids. The active metabolites of Butamirate Citrate have also antitussive action.
Bidicod is indicated in acute cough of any etiology, suppression of pre-& post-operative cough in surgery & bronchoscopy and suppression of whooping cough.
Route of administration: Oral:
Bidicod Syrup: Children 3-6 years of age: 5 ml 3 times daily.
Children 6-12 years of age: 10 ml 3 times daily.
Adolescent (over 12 years of age): 15 ml 3 times daily.
Adults: 15 ml 4 times daily.
With medicine: Concomitant use of expectorants may lead to retention of mucous in the respiratory system, which can increase the risk of bronchospasm and airway infection. With food & other: No adequate data is found.
Overdose:
Accidental overdose with Butamirate Citrate can cause the following symptoms: drowsiness, nausea, vomiting, diarrhoea, loss of balance and hypotension. Standard emergency procedures should be followed: activated charcoal, saline laxatives and standard cardio-respiratory resuscitation.
Butamirate Citrate should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. As a general rule, for safety reasons, in the absence of data on elimination of the active substance in breast milk, the benefits of Butamirate Citrate administration during lactation should be carefully weighed against the risks.
See the dose and administration.
Avoid simultaneous administration of expectorants. Avoid during pregnancy (1st 3 months).
Store below 30° C temperature and cool and dry place, away from light. Keep out of the reach of children.